Nur A. Shah
8613-114 St
Edmonton, AB, Canada
Edmonton, AB, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
DMD-Null mice exhibit severe muscle weakness, impaired regeneration, and deficient satellite cell function.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 16, 2026
DG9-Conjugated Morpholino-Based Exon 51-Skipping Therapy for Duchenne Muscular Dystrophy.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: October 01, 2025
Lipid nanoparticle delivery of antisense gapmers attenuates pathology in a mouse model of facioscapulohumeral muscular dystrophy.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 17, 2025
DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function.
Journal: Nature communications
Published: April 02, 2024
Cardiac therapies for Duchenne muscular dystrophy.
Journal: Therapeutic advances in neurological disorders
Published: December 15, 2022
Restoring Dystrophin Expression by Skipping Exons 6 and 8 in Neonatal Dystrophic Dogs.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: November 18, 2022
Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 15, 2021
Natural History of a Mouse Model Overexpressing the Dp71 Dystrophin Isoform.
Journal: International journal of molecular sciences
Published: November 02, 2021
eSkip-Finder: a machine learning-based web application and database to identify the optimal sequences of antisense oligonucleotides for exon skipping.
Journal: Nucleic acids research
Published: March 05, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026